On July 9, Fangzhou Inc (06086.HK) , a member company of Volcanics Venture and "China's largest online chronic disease management platform", was officially listed on the main board of the Hong Kong Stock Exchange . The initial offering price was 8.18 yuan per share, and the company's market value was 11 billion Hong Kong dollars.
Fangzhou Inc owns the chronic disease management brand "Fangzhou Jianke", which has been focusing on chronic disease management for many years to meet the needs of patients with chronic diseases (such as hypertension, cardiovascular and chronic respiratory diseases). It mainly provides comprehensive medical services, online retail pharmacy services, customized content and marketing solutions.
China has a huge population base of chronic diseases. As the aging population deepens, the demand for chronic disease management services will be even stronger in the future. However, the current public medical resources are unable to meet the growing demand for chronic disease management, and there is still a huge gap. According to data from Frost & Sullivan, the overall scale of China's chronic disease management market will continue to grow at an annual compound rate of 10.5%, reaching RMB 15 trillion in 2030. More and more people are willing to "pay" on the Internet chronic disease management platform to obtain higher quality chronic disease diagnosis and treatment services.
There is a huge demand for chronic disease management and the market potential is unlimited. As an innovative enterprise with the "acquaintance doctor-patient model" as its core, Fangzhou is leading the profound changes in the chronic disease management industry. The core of Fangzhou's innovative digital chronic disease management model is the "acquaintance doctor-patient model". Through the H2H service platform it has built, it provides patients with personalized and convenient services and also provides doctors with efficient and accurate management tools. This innovative doctor-patient relationship model has not only attracted a large number of doctors to join, but also won wide recognition from patients.
The prospectus shows that the number of registered users on Fangzhou's platform has reached 42.7 million, of which more than 8.4 million are monthly active users. This data also makes Fangzhou the largest digital chronic disease management platform in China. On the other hand, the number of paying users of Fangzhou's H2H service platform will increase from 2.5 million to 4.4 million from 2021 to 2023, with a user retention rate of 79% and a user conversion rate of 36.2%, which is highly competitive in the industry.
On the other hand, Fangzhou has more than 210,000 professional registered doctors from 15,600 medical institutions in China. They provide effective and long-term chronic disease management for patients on the platform, respond to patients' online consultations in a timely manner, and adjust treatment plans in a timely manner based on their medication and health conditions, thereby improving their management efficiency, alleviating the burden on domestic public medical care, and becoming an effective supplement to medical resources.
Pictured is Zhang Suyang (first from left), founding managment partner of Volcanics Venture, attending the listing ceremony
Zhang Suyang, founding management partner of Volcanics Venture, pointed out that as China's population ages, the number of patients with chronic diseases is increasing rapidly. The "Report on the National Plan for Monitoring Chronic Diseases among Residents during the 13th Five-Year Plan" predicted that by 2023, this number will exceed 480 million, accounting for 30.5% of the total population. This change has directly driven the huge demand for chronic disease management services.
" Against this background, Fangzhou Inc's H2H (Hospital to Home) model is particularly important in the field of chronic disease management. This model provides patients with more convenient and personalized health management solutions by extending medical services from hospitals to homes. It is based on the recognition of the potential of this model and the confidence in its future development that we chose to invest in Fangzhou Inc in 2017. We firmly believe that with the continuous growth of market demand and the continuous advancement of technology, Fangzhou Inc will show stronger growth momentum in the future. " Zhang Suyang said.
Fangzhou stated that as a large-scale domestic Internet chronic disease management platform, the company will continue to integrate medical and pharmaceutical resources, continuously improve user experience and chronic disease management quality, promote the high-quality development of the chronic disease management industry, and strive to continuously improve shareholder returns.
Comments